Phio Pharmaceuticals Alleviates Going Concern Doubt with $20.6M Financing and Positive PH-762 Phase 1b Clinical Data
PHIO sits 46% above its 52-week low of $0.813 on light trading volume (0.2× avg).
Summary
Phio Pharmaceuticals reported its 2025 annual results, highlighting successful capital raises totaling $20.6 million that resolved going concern doubts and positive Phase 1b clinical data for its lead cancer therapeutic, PH-762.
Key Events · Earnings and Guidance · PHIO
-
Going Concern Doubt Alleviated
The company successfully raised $20.6 million through multiple financings in 2025, providing sufficient cash and cash equivalents to meet planned obligations for at least 12 months and alleviating prior going concern doubts.
-
Significant Capital Raise
Net proceeds from financing activities in 2025 totaled $20.6 million, a substantial amount relative to the company's market capitalization, significantly bolstering its liquidity.
-
Positive PH-762 Phase 1b Clinical Data
The lead candidate, PH-762, showed an overall response rate of 65% in cutaneous squamous cell carcinoma (cSCC) patients in its Phase 1b trial, with a good safety profile and no dose-limiting toxicities. An FDA submission for next clinical steps is targeted for Q2 2026.
-
Increased Net Loss and Dilution
The net loss for 2025 increased to $8.7 million from $7.2 million in 2024, reflecting increased R&D and G&A expenses. Shares outstanding significantly increased from 1.7 million to 11.6 million due to the financings, resulting in substantial dilution.
Analysis · PHIO · Life Sciences
This annual report is highly significant for Phio Pharmaceuticals, a clinical-stage biopharmaceutical company. The successful completion of multiple financings in 2025, raising $20.6 million, has enabled the company to alleviate substantial doubt about its ability to continue as a going concern, a critical positive development for a small-cap biotech. Furthermore, the report provides encouraging Phase 1b clinical data for its lead candidate, PH-762, showing a 65% overall response rate in cutaneous squamous cell carcinoma with a favorable safety profile. This clinical progress, coupled with a strengthened cash position, significantly de-risks the company's near-term operations and provides a runway for continued development. Investors should monitor the upcoming FDA submission for PH-762 and future financing needs.
At the time of this filing, PHIO was trading at $1.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.6M. The 52-week trading range was $0.81 to $4.19. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.